Navigation Links
JAK inhibitor provides rapid, durable relief for myelofibrosis patients
Date:9/15/2010

HOUSTON - An oral medication produces significant and lasting relief for patients with myelofibrosis, a debilitating and lethal bone marrow disorder, researchers at The University of Texas MD Anderson Cancer Center report in the Sept. 16 New England Journal of Medicine.

Myelofibrosis is caused by the accumulation of malignant bone marrow cells that trigger an inflammatory response, scarring the bone marrow and limiting its ability to produce blood, causing anemia.

"The problem with myelofibrosis is the lack of available therapies for patients - there are none approved for this disease today," said principal investigator Srdan Verstovsek, M.D., Ph.D., associate professor in M. D. Anderson's Department of Leukemia. Average life expectancy for people with this disease is 5 to 7 years. Available therapies approved for other diseases provide little response and are mainly palliative.

"This experimental drug is the first to target one of the underlying abnormalities in the malignant cells that cause myelofibrosis," Verstovsek said. "It provides unprecedented reduction of enlarged spleens that are a central characteristic of the disease, and relieves pain, fatigue and other symptoms, improving quality of life."

Swollen spleens cause pain, malnutrition

"Interestingly, other organs, mainly the spleen, attempt to take over the production of blood cells. Bone marrow forms in the spleen," Verstovsek said. Malignant cells also accumulate there. "The growing spleen causes significant problems for the patient, and not just because it's painful. It compresses the stomach and bowels, so patients suffer malnutrition and lose weight. The ability to walk and to bend is affected, and the body deteriorates overall."

End-stage patients resemble the severely malnourished, with bloated abdomens and thin limbs. Patients on the study gained weight while on the medication.

The phase I/II clinical trial of INCB018424
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. BRAF inhibitor shows promising preclinical activity against melanoma
2. Patients Who Take a Proton-Pump Inhibitor With Medicine to Prevent Blood Clots Are Less Likely to Be Hospitalized for Bleeding Ulcers
3. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
4. Suite 101.com Provides Insight Into Consumer Reading Behavior Online
5. Ochsner Health System Connects Community Physicians to Electronic Medical Records; Orion Health HIE Solution Provides Access to Healthcare Providers Across the Gulf South
6. Pets Guardian Provides A Pet Safety System, Ensuring Pets Will Be Cared For In Case of a Personal Emergency
7. International liver cancer congress provides possible solutions to reduce significant burden
8. Principal Protected Index Investing Provides Innovative Method to Significantly Reduce Stock Market Loss and Risk
9. Progesterone is effective for hot flash treatment and provides an alternative to estrogen
10. What's The Best Whole House Water Purification System? Sweetwater LLC Provides Comparison
11. New Web Site Provides Helpful Exercise and Nutrition Tips
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 In Pretrial Order #139 (Scheduling ... discovery conferences would be beneficial in this [MDL].” Accordingly, ... “At the end of December,” the order further provides, ... additional conferences. , “The plain import of this ... still much to be discussed as these cases progress ...
(Date:9/17/2014)... Dennis Thompson HealthDay ... -- Exposure in the womb to household chemicals known ... developing asthma, Columbia University researchers reported in a new ... risk of developing asthma between age 5 and 11 ... levels of two phthalates (pronounced thal-ates), the researchers found. ...
(Date:9/17/2014)... Scripps Research Institute (TSRI) have devised a new ... against vancomycin-resistant strains of MRSA and other disease-causing ... have not one but two distinct mechanisms of ... resistance quickly. , "This is the prototype of ... clinical use a generation or maybe even two ...
(Date:9/17/2014)... York, New York (PRWEB) September 17, 2014 ... filings involving the Conserve line of metal-on-metal hip ... now underway in U.S. District Court, Northern District ... an updated Case List issued by the U.S. ... 2014, at least 397 product liability claims have ...
(Date:9/17/2014)... Toledo, Ohio (PRWEB) September 17, 2014 ... hearing for today, September 17, 2014, to consider: , ... Testosterone Replacement Therapy (TRT), and, 2. ... of TRT. , With the TRT litigation ongoing, an ... FDA on the dangers of testosterone replacement therapy. Among ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2
... From June Dairy Month through,the State Fair, summer ... June 1, Minnesotans will be able get details about ... mouse. ExploreDairy.com is a,one-stop resource for all the latest ... hardworking dairy farm families., ExploreDairy.com is designed to ...
... 29 The following is a,statement by Matthew L. ... Health Organization,s World No Tobacco Day, to be celebrated,May ... of the global,tobacco epidemic and the urgent need for ... save lives., This year,s theme -- Tobacco-Free Youth: ...
... May 29 The Academy of General,Dentistry (AGD) expresses ... reauthorize the Dental Health Improvement Act (S,3067) for another ... and Benjamin Cardin (D-MD). The intent of the Act ... shortage of dental health,professionals., "Last week was a ...
... Leaders of Indiana and Purdue universities Thursday ... Translational Sciences Institute (CTSI), a medical research initiative ... business and government to swiftly transform discoveries into ... National Institutes of Health has awarded a five-year ...
... The Musculoskeletal Transplant,Foundation (MTF) will provide military hospitals ... joint repair for injured servicemen and,women., Military ... obtaining,tissue used for cartilage transplantation and meniscus grafts ... types of tissue are in high,demand for U.S. ...
... NY) The National Institutes of Health has ... University and Montefiore Medical Center one of its ... million over five years. The grant will support ... Research (ICTR), whose overarching goal is to collaboratively ...
Cached Medicine News:Health News:ExploreDairy.com Debuts With Information on Minnesota Dairy Events, People and Products 2Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 2Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 3Health News:AGD Thanks Senators for Introducing Bill to Reauthorize the Dental Health Improvement Act 2Health News:NIH awards Einstein College of Medicine & Montefiore Medical Center $22M grant 2Health News:NIH awards Einstein College of Medicine & Montefiore Medical Center $22M grant 3
(Date:9/17/2014)... LAWRENCEVILLE, N.J. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... that details how to implement GS1 Standards to ... (DSCSA), and enhance patient safety and security in ... Applying GS1 Standards to U.S. Pharmaceutical Supply ... Chain Security Act , was developed in ...
(Date:9/17/2014)... Sept. 17, 2014 Isis Pharmaceuticals, Inc. ... has earned a $4 million milestone payment from ... with the initiation of a Phase 3 study ... (MDR), gram-negative bacterial infections.  The Phase 3 study ... the efficacy and safety of plazomicin compared to ...
(Date:9/17/2014)... FRANCISCO , Sept. 17, 2014 Sutro ... bispecific antibodies, and the biopharmaceutical division of Merck KGaA, ... EMD Serono in the United States ... a collaboration and license agreement to develop antibody drug ... to a cytotoxic drug. The antibody is thought to ...
Breaking Medicine Technology:New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... The Board of Directors of Stereotaxis, Inc. (NASDAQ: ... that it reaffirmed the Company,s plans for both the launch ... Odyssey ™  platform into standard labs. "At ... commercial strategies put forth for the launch of Epoch, as ...
... 2011 Reportlinker.com announces that a new market ... Pharmaceutical Manufacturers - India ... This register contains information about 1327 ... includes the following details of the manufacturers: ...
Cached Medicine Technology:Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 2Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 3
Hemagglutination slide test for the qualitative detection and quantitative determination of antibodies to streptococcal extracellular antigens in serum, plasma, or whole blood....
Color-enhanced slide agglutination test for the rapid qualitative and semi-quantitative detection of antistreptolysin O....
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
Hemagglutination slide test for the qualitative and quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
Medicine Products: